EP Patent

EP4326269A4 — Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative diseases

Assigned to Oregon Health and Science University · Expires 2025-08-20 · 1y expired

What this patent protects

Patent listed against ponatinib-hydrochloride.

Drugs covered by this patent

ponatinib-hydrochloride (PONATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: EP4326269A4
Jurisdiction: EP
Classification: —
Expires: 2025-08-20
Drug substance claim: No
Drug product claim: No
Assignee: Oregon Health and Science University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.